What Does Wall Street Think About BioMarin Pharmaceutical (BMRN)?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best strong buy growth stocks to buy now. On August 19, Bernstein analyst William Pickering maintained a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and set a price target of $95.00.

Similarly, Evercore ISI analyst Cory Kasimov also maintained a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on August 11, setting a price target of $110.00.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has an analyst consensus of Strong Buy, with its median price target of $57.48 implying an upside of 70.49% from current levels.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) develops and commercializes therapies for serious and life-threatening medical conditions and rare diseases. The company’s product pipeline includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307.

While we acknowledge the potential of BMRN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.